Sales less than 2m below ABGSCe 30m EBITDA better than expected (SEK 0m vs.
Redeye comments on Formpipe’s Q4, with a soft adjusted EBIT as previously announced.
Redeye considers Arise’s Q4 2024 report to be better than expected despite facing tough comps, prima...
Redeye's provides its initial take on Genovis' year-end report which came in softer than we had esti...
Sales SEK 42m and EBIT SEK -3.7m (vs. ABGSCe 36m and -2.
Redeye interviews Mentice’s CEO Frans Venker and CFO Ulrika Drotz Voksepp.
Redeye returns with a more in-depth take on the Q4 report.
Minor estimate changes Potential start of variable revenue acceleration EV/ARR 2x, '25e EV/EBITDA ~8...
Redeye makes positive revisions to its financial projections and fair value range following Stille's...
Redeye provides an update on Acarix following its year-end report, which showed softer-than-expected...
Redeye updates on G5 following its Q4-report where revenue was in line while EBIT was better than ex...
Redeye comments on Alligator Bioscience's Q4 report and the rights issue, which was subscribed to 54...
Atria's Q4 fell short of expectations, but we believe it has reached a sustainably higher margin lev...
Redeye provides an update following SenzaGen’s Q4 2024 report.
Redeye provides an update following Optomed’s Q4 report.
Redeye provides its comment on Mendus’ Q4 2024 report.
CapMan's Q4 was solid across the board, with both Management company business fee income and adjuste...
Strong EBIT of SEK 437m (ABGSCe 495m) in Q4 New targets: 15% ROE and total '25-'27 EBIT SEK 1.
Redeye endorses today’s news that the European Commission has approved Emcitate for “the treatment o...
Redeye returns following IRLAB's Q4 report and recent news in the company.
